Antiparkinsonian Activity of Benzenesulfonamide Derivatives, Selective MAO-B Inhibitors

The anti-parkinsonian activity of benzolsulfonamide selective MAO-B inhibitors was evaluated in a model of experimental parkinsonism in white mice (systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPTP). Six candidate compounds (laboratory codes S6-S8 and S11-S13) were analyz...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Bulletin of experimental biology and medicine Ročník 179; číslo 3; s. 312 - 316
Hlavní autoři: Khokhlov, A. L., Fedorov, V. N., Shetnev, A. A., Korsakov, M. K., Petukhov, S. S., Vdovichenko, V. P., Khokhlova, A. A., Suleimanov, S. Sh
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York Springer US 01.07.2025
Springer Nature B.V
Témata:
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Amine oxidase (flavin-containing)
Animals
Antiparkinson Agents - chemistry
Antiparkinson Agents - pharmacology
Antiparkinson Agents - therapeutic use
Basal ganglia
Biomedical and Life Sciences
Biomedicine
Cell Biology
Central nervous system diseases
Disease
Disease Models, Animal
Dopamine
Drug dosages
Drug therapy
Emotional behavior
Indans - pharmacology
Internal Medicine
Laboratory Medicine
Male
Mice
Monoamine Oxidase - metabolism
Monoamine Oxidase Inhibitors - chemistry
Monoamine Oxidase Inhibitors - pharmacology
Monoamine Oxidase Inhibitors - therapeutic use
Movement disorders
MPTP
Normal distribution
Parkinson's disease
Pathogenesis
Pathology
Pharmaceuticals
Rasagiline
Sulfonamides - chemical synthesis
Sulfonamides - chemistry
Sulfonamides - pharmacology
benzenesulfonamide derivative
MAO inhibitors
Parkinson’s disease
experimental parkinsonism
ISSN:0007-4888, 1573-8221, 1573-8221
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The anti-parkinsonian activity of benzolsulfonamide selective MAO-B inhibitors was evaluated in a model of experimental parkinsonism in white mice (systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPTP). Six candidate compounds (laboratory codes S6-S8 and S11-S13) were analyzed. Rasagiline was used as the reference drug. Only compound S13 was comparable to rasagiline in preventing the development of rigidity and hypokinesia in animals and surpassed the reference drug in correcting emotional and behavioral activity.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-4888
1573-8221
1573-8221
DOI:10.1007/s10517-025-06480-1